Eribulin in the management of inoperable soft-tissue sarcoma: patient selection and survival.
Patients diagnosed with metastatic soft-tissue sarcoma (STS) have a poor prognosis. Additionally, after failure of first-line therapy, there are relatively few treatment options from which to choose. The novel tubulin-binding drug, eribulin, with a unique mechanism of action from taxanes or vinca alkaloids, has shown clinical activity in several different types of cancers. Eribulin has been approved by the US Food and Drug Administration (FDA) for patients with metastatic breast cancer previously treated with an anthracycline or a taxane and has recently been FDA approved for patients with unresectable or metastatic liposarcoma who have failed a previous anthracycline regimen. Here, we review current standard treatments of STS, a background of eribulin, the studies that have propelled eribulin to FDA approval for liposarcoma, and future directions of the drug. The benefits of eribulin in STS are discussed in detail, especially with regard to the recent pivotal Phase III study comparing eribulin to dacarbazine for leiomyosarcoma and adipocytic sarcoma.
Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Colin
C
Thomas
Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Sujana
S
Movva
eribulin; soft-tissue sarcoma; tubulin-binding drugs
Lancet. 2016 Apr 16;387(10028):1629-37
26874885
Cancer Res. 2004 Aug 15;64(16):5760-6
15313917
Cancer. 2011 Mar 1;117(5):1049-54
20945333
Lancet. 2012 May 19;379(9829):1879-86
22595799
Clin Cancer Res. 2009 Jun 15;15(12 ):4213-9
19509146
Ann Surg. 1999 May;229(5):602-10; discussion 610-2
10235518
Lancet. 2011 Mar 12;377(9769):914-23
21376385
Crit Rev Oncol Hematol. 2012 Feb;81(2):163-84
21493087
Invest New Drugs. 2008 Apr;26(2):175-81
17898927
Cancer. 1995 Jan 1;75(1 Suppl):395-405
8001010
Cancer. 2012 May 1;118(9):2403-10
21935916
J Clin Oncol. 2007 Jul 1;25(19):2755-63
17602081
Mol Cancer Ther. 2005 Jul;4(7):1086-95
16020666
Mol Pharmacol. 2006 Dec;70(6):1866-75
16940412
Br J Cancer. 2015 Dec 1;113(11):1534-40
26554651
J Clin Oncol. 2007 Jul 20;25(21):3144-50
17634494
Breast Cancer Res Treat. 2015 Dec;154(3):509-20
26567010
J Clin Oncol. 1985 Mar;3(3):353-66
3973646
Cancer Res. 2011 Jun 1;71(11):3952-62
21498637
J Clin Oncol. 1987 Jun;5(6):840-50
3585441
Lancet Oncol. 2011 Oct;12 (11):1045-52
21937277
Anticancer Res. 2012 May;32(5):1611-9
22593439
Eur J Cancer. 2002 Mar;38(4):543-9
11872347
Nat Rev Cancer. 2005 Jun;5(6):423-35
15928673
Med Pediatr Oncol. 1975;1(1):63-76
1232527
J Clin Oncol. 2016 Mar 10;34(8):786-93
26371143
Breast Cancer Res Treat. 2014 Dec;148(3):553-61
25381136
Br J Cancer. 2014 Mar 18;110(6):1497-505
24569463
Nat Prod Rep. 2013 Sep;30(9):1158-64
23896896
Cochrane Database Syst Rev. 2003;(3):CD003293
12917960
Clin Cancer Res. 2009 Jun 15;15(12 ):4207-12
19509177
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
25559415
Cancer Sci. 2014 Oct;105(10 ):1334-42
25060424
Cancer. 1994 May 15;73(10):2506-11
8174046
Clin Sarcoma Res. 2015 May 16;5:13
25987978
Eur J Cancer. 2005 Dec;41(18):2853-60
16289617
Cancer. 2005 Jul 15;104(2):361-6
15948172
Lancet. 2016 Apr 16;387(10028):1594-6
26874886
Am J Pathol. 2015 Feb;185(2):550-62
25478808
J Clin Oncol. 2009 Jun 20;27(18):2954-61
19349550
Lancet Oncol. 2014 Apr;15(4):415-23
24618336
Biochemistry. 2010 Feb 16;49(6):1331-7
20030375
Ann Oncol. 2012 May;23 (5):1241-9
21903605
J Clin Oncol. 2015 Feb 20;33(6):594-601
25605862
Clin Cancer Res. 1996 Nov;2(11):1843-9
9816139
Cancer Res. 2001 Feb 1;61(3):1013-21
11221827